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Introduction
Carcinoma of the cervix (Cx Ca) remains a leading cause
of cancer mortality in women worldwide. Approximately
500,000 women develop cervical cancer every year,
resulting in an annual mortality of about 200,000 [1].
In Taiwan, cervical cancer is not only the most frequently
reported cancer among women [2], but is also the
most common female genital tract neoplasm [3,4], with
an incidence of 16 per 100,000 women in 2002 [5].
Radical hysterectomy plus pelvic lymph node dissection
is the standard treatment when disease is detected at
an early stage (stages IA2–IIA). Concurrent chemo-
radiotherapy (CCRT) remains the standard for locally-
advanced disease (stages IIB–IVA) [6]. Patients with
recurrent Cx Ca are difficult to treat with surgery and
radiotherapy alone owing to the presence of distant
metastases, and single-agent cisplatin represents the
most common treatment option and most effective
chemotherapeutic agent for treating recurrent or 
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SUMMARY
Objective: To investigate the objective response rate to and tolerance of biweekly Lipo-Dox (TTY Biopharm Co.
Ltd., Taipei, Taiwan) at a dosage of 20 mg/m2 in previously treated patients with recurrent cervical cancer.
Materials and Methods: This study was performed as a Simon’s two-stage phase II clinical trial. Ten patients
with recurrent cervical cancer were enrolled between April 2003 and December 2005 at the Mackay Memorial
Hospital. Lipo-Dox (20 mg/m2 intravenous) diluted in 250 mL of 5% dextrose solution was administered at 
2-weekly intervals.
Results: The mean age of the patients was 51 ± 11.1 years. The mean number of cycles of Lipo-Dox injection was
4.6 (range, 1–12 cycles). Nine patients (90%) had disease progression. Only one patient (10%) achieved a partial
response, and this was also the only patient who experienced WHO grade 2 palmar-plantar erythrodysesthesia,
which led to treatment delay for 2 months. The median survival time was 2 months (range, 2–6 months). The
majority of patients experienced grade 1 or 2 anemia (30%), leukopenia (20%) or thrombocytopenia (20%),
and others exhibited symptoms of nausea and vomiting (30%).
Conclusion: Salvage chemotherapy with Lipo-Dox at a dose of 20 mg/m2 administered at 2-weekly intervals
produced limited responses in patients with recurrent cervical cancer. This trial will not proceed to the second
stage. These results may discourage the management of recurrent cervical cancer with single-agent Lipo-Dox in
future clinical trials. [Taiwan J Obstet Gynecol 2008;47(3):322–326]
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metastatic Cx Ca. Most patients achieve a clinically com-
plete (CR) or partial response (PR) with cisplatin-based
regiments. The response rates to cisplatin range from
40–60%, with average progression-free and overall sur-
vivals of 4.1 and 6.7 months, respectively [7]. In addi-
tion, the clinical application of cisplatin often results
in obstructive uropathy and renal toxicity, which limits
its use in some women. There is, therefore, an urgent
need to identify new chemotherapeutic agents that are
less toxic and have higher response rates and longer
response durations for treating platinum-resistant
squamous cell carcinoma (SCC) of the cervix.
Polyethylene glycol-coated (pegylated) liposomal
doxorubicin (PLD) is designed for the delivery of a
liposomal form of doxorubicin [8] (Caelyx, Schering
Plough International, Kenilworth, NJ, USA) to the sites
of solid tumors [9]. The efficacy of PLD in women has
already been demonstrated in studies of ovarian carci-
noma [10–12], breast cancer [13], and Kaposi sar-
coma [14]. Lower risks of musculoskeletal disorders
and alopecia, and fewer grade 3/4 toxicities have been
shown in women with relapsed ovarian cancer when
comparing single-agent PLD with paclitaxel [10] and
topotecan [11,12], respectively.
Lipo-Dox (TTY BioPharm, Taipei, Taiwan) is a 
second-generation PLD drug containing distearoylphos-
phatidylcholine that has been commercially available
in Taiwan since 1998. We have recently demonstrated,
in a multicenter phase II trial, that Lipo-Dox at 45 mg/m2
every 4 weeks is effective against recurrent, platinum-
resistant epithelial ovarian cancer [15]. The purpose
of this study was to extend these previous findings by
investigating the activity of biweekly Lipo-Dox (20 mg/
m2) in previously treated patients with recurrent Cx Ca
at a single institution.
Materials and Methods
Previously treated patients diagnosed with recurrent
Cx Ca between April 2003 and December 2005, and
aged 18–75 years were eligible for inclusion in the
study. Diagnoses were confirmed either by radiologic
imaging studies (chest X-ray, computed tomography,
technetium Tc 99 whole body bone scan) or by ele-
vated tumor markers (SCC, carcinoembryonic antigen
[CEA] or CA-125). All selected patients were required
to fulfill the following diagnostic criteria: bone mar-
row function (granulocyte count > 1,500/mm3; platelet
count > 100,000/mm3), renal function (creatinine level
< 2.5 mg/dL), liver function (bilirubin and liver transam-
inases < 3.0 times the upper limit of institutional nor-
mal), cardiac function (left ventricular ejection fraction
> 50%), and Karnofsky performance status (> 60%).
Detailed information on the patients was obtained
directly from individual medical records and was care-
fully reviewed. Follow-up information was obtained
from chart review of records of clinic visits and from
correspondence with patients and physicians. Disease-
free survival was defined as the period from the start
of primary treatment until clinical or radiologic evidence
of recurrence. The follow-up time was defined as the
time from initial diagnosis to the time of death or last
follow-up. All surviving patients were followed up until
June 2006.
Each vial of Lipo-Dox contained 20 mg of PLD. Intra-
venous premedication was administered with 20 mg
dexamethasone (Decadron; NV Organon, Oss, The
Netherlands), 50 mg diphenhydramine hydrochloride
(Vena; YF Chemical Corp., Taipei, Taiwan), and 300 mg
cimetidine (Tagamet; GlaxoSmithKline, London, UK)
30 minutes before PLD infusion. Lipo-Dox (20 mg/m2)
was diluted in 250 mL of 5% dextrose solution and was
administered by intravenous infusion over 30 minutes
at 2-weekly intervals. Granulocyte colony-stimulating
factor was not recommended for prophylactic use but
was allowed if grade 4 neutropenia occurred. Patients’
responses were measured by pelvic examination,
tumor markers (SCC, CEA or CA-125), and radiologic
imaging studies including computed tomography
scan. The laboratory examinations included complete
blood counts and blood chemistry. Complete blood
counts were performed biweekly to assess hematologic
recovery. Treatment was delayed in patients experienc-
ing serious hematologic and/nonhematologic toxicity.
Patients were withdrawn from the study when evi-
dence of disease progression or grade 3 toxicity was
observed during treatment. Safety and toxicity were re-
corded and graded according to the Common Toxicity
Criteria (version 2.0) of the U.S. National Cancer
Institute. A CR was defined as complete disappear-
ance of all evidence of disease (including image and
tumor markers) for at least 4 weeks. A PR was defined
as a > 50% decrease in the size of measurable lesions or
the reduction of tumor markers for at least 4 weeks.
Stable disease was defined as a reduction of < 50% or
an increase of < 25% in the tumor size or tumor markers
over a period of ≥ 3 months, and progressive disease
was defined as an increase of > 25% in the tumor size
or tumor markers compared with pretreatment values.
All relevant data required for calculating response
rates and survivorship were collected in this study.
The clinical trial was approved by the Institutional
Review Boards and Ethics Committees of Mackay
Memorial Hospital. Written informed consent in line with
institutional guidelines was obtained at enrollment.
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Statistics
This was a Simon’s two-stage phase II clinical trial
designed to evaluate the responses to Lipo-Dox in
patients with recurrent Cx Ca. The sample size was cal-
culated based on a hypothesized null proportion of
10%, 80% power, and type I error of 0.05. It allowed
for the study to terminate prematurely if the test regi-
men was not effective. A tumor response rate of 30%
was assumed in patients who received the study regi-
men. The accrual of ten patients would proceed to the
second stage if treatment responses are observed in ≥
two patients in the first stage, otherwise the trial would
be terminated at the first stage. An additional 19
patients will be recruited for the second stage, and ≥ six
of these 29 patients would be required to show responses
to conclude that the study regimen is effective.
Results
Ten patients with recurrent Cx Ca were enrolled in this
clinical trial between April 2003 and December 2005
at the Mackay Memorial Hospital. All patients were
adult females with a mean age of 51 ± 11.1 years (range,
33–67 years) at initial diagnosis. The most frequent
histologic type was SCC (6/10, 60%), followed by adeno-
carcinoma (3/10, 30%) and adenosquamous carcinoma
(1/10, 10%). The tumors were originally clinically staged
as FIGO stage IB1 (6/10, 60%), stage IB2 (1/10, 10%),
and stage IIA (3/10, 30%). All patients had received at
least one line of chemotherapy with a platinum com-
pound prior to study entry: six patients had received
one chemotherapeutic regimen, two had received two
regimens, one had received three regimens, and one
patient had received six regimens. These patients were
treated either by radical hysterectomy plus bilateral
pelvic lymphadenectomy (7/10, 70%); weekly cisplatin
CCRT at 40 mg/m2/week (2/10, 20%); or by total
abdominal hysterectomy with postoperative CCRT
(1/10, 10%). The median disease-free survival period
was 11 months (range, 4–37 months) after primary
treatment. The patients received salvage chemotherapy
with PLD after confirmed recurrence. The clinical char-
acteristics, treatment modalities and outcome data of
individual patients were organized according to clinical
stage, as shown in the Table.
A total of 46 courses of PLD were administered
with a mean of 4.6 (range, 1–12) per patient. Only
patient 9 (1/10, 10%) achieved PR with stationary
tumor markers (CEA and SCC). This patient, who had
a FIGO stage IIA SCC, received 12 cycles of Lipo-Dox.
This was also the only patient who experienced WHO
grade 2 palmar-plantar erythrodysesthesia (PPE) after
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six cycles of Lipo-Dox injection (Figure), which delayed
the next course of injections by 2 months. Nine patients
(90%) had progressive disease. The majority of patients
experienced grade 1 or 2 anemia (30%), leukopenia
(20%) or thrombocytopenia (20%), and others exhib-
ited symptoms of nausea and vomiting (30%). Five
patients (50%) withdrew from the study after at least
four cycles as a result of grade 3 neutropenia (three
patients), grade 3/4 toxicities (one patient), and grade
3 thrombocytopenia (one patient). No cases of grade
3/4 leukopenia, thrombocytopenia or cardiotoxicity
were observed. Four patients died after short-term
treatment with Lipo-Dox (2–4 cycles) (4/10, 40%). The
total response rate was 10% and the median survival
time was 2 months (range, 2–6 months).
Discussion
Very few studies have addressed the activity of PLD 
in recurrent/metastatic pretreated Cx Ca. PLD pro-
duces higher intratumoral drug concentrations (4- to
11-fold), a longer circulation time, and better thera-
peutic responses than the free form of doxorubicin,
and has a lower renal toxicity profile than cisplatin
[16–18]. Verschraegen et al, in a phase II trial, reported
a response rate of 38% with a combination of carbo-
platin plus PLD in 29 patients with recurrent SCC of
Cx Ca [9]. However, Ferrandina et al reported a lim-
ited response rate in recurrent Cx Ca patients treated
with PLD, and they terminated their clinical trial [19].
A Gynecologic Oncology Group phase II study [20]
using Doxil (40 mg/m2) as second-line chemotherapy
for SCC of the cervix was conducted to determine the
level of activity in women with advanced and recurrent
cervical cancer. Although 26 patients entered the study,
only three (11.1%) had PR, which was similar to the
result in our study, where only one patient achieved PR
(10%). The present data demonstrated that PLD had
little activity in these patients in terms of overall response
rate. Similar to studies reported by other researchers
with recurrent epithelial ovarian carcinoma [10,11], the
most common side effects for recurrent Cx Ca patients
treated with PLD were nonhematologic, including
stomatitis and PPE. PPE (also called hand-foot syn-
drome) is a cutaneous reaction typically involving the
palms of the hands and soles of the feet. In our study,
only one patient (10%) experienced nonhematologic
toxicity, consisting of mild grade 2 PPE. The relatively
low rate and low grade of PPE can be explained by 
the low-dose PLD administration. Most toxicities were
grade 1 or 2. Lipo-Dox caused minor leukopenia, ane-
mia, and thrombocytopenia. Grade 3 or 4 leukopenia
or thrombocytopenia was not observed in this study.
Salvage chemotherapy with Lipo-Dox at a dose of
20 mg/m2 every 2 weeks resulted in a limited response
in patients with recurrent Cx Ca. This trial will not pro-
ceed to the second stage. These results may discourage
the management of recurrent Cx Ca with single-agent
Lipo-Dox in future clinical trials. However, the minimal
hematologic toxicity of Lipo-Dox makes it an important
candidate for incorporation with other chemothera-
peutic agents, especially for the palliation, rather than
the cure, of recurrent Cx Ca. Nevertheless, alternate
chemotherapeutic agents or combination regimens
with minimal renal toxicity are still an ongoing goal for
future studies.
References
1. Bosch FX, Manos MM, Munoz N, et al. Prevalence of
human papillomavirus in cervical cancer: a worldwide per-
spective. International Biological Study on Cervical Cancer
(IBSCC) Study Group. J Natl Cancer Inst 1995;87:796–802.
2. Chen HS, Yang YC, Su TH, Wang TY, Huang YW. Human
papillomavirus testing (hybrid capture II) to detect high-
grade cervical intraepithelial neoplasia in women with
mildly abnormal papanicolaou results. Taiwan J Obstet Gynecol
2005;44:252–7.
3. Cheng WF. Human papillomavirus vaccine for cervical 
cancer: where are we now? Taiwan J Obstet Gynecol 2005;
44:232–41.
4. Wang PD, Lin RS. Epidemiology of cervical cancer in
Taiwan. Gynecol Oncol 1996;62:344–52.
5. Bureau of Health Promotion, Department of Health,
Taiwan. November 16, 2006. Available at: http://www.bhp.
doh.gov.tw/asp/themeParkId=510/960305/pdf/951116.pdf
[Date accessed: March 22, 2007]
6. Tseng CC, Tseng CJ, Chang CC, et al. Human papilloma-
virus deoxyribonucleic acid sequences and clinical outcomes 
Taiwan J Obstet Gynecol • September 2008 • Vol 47 • No 3 325
Salvage Chemotherapy in Recurrent Cx Ca with Lipo-Dox
Figure. Patient 9 developed WHO grade 2 palmar-plantar
erythrodysesthesia after six cycles of Lipo-Dox injection.
Taiwan J Obstet Gynecol • September 2008 • Vol 47 • No 3326
J.R. Chen, et al
of cervical cancer patients following radiotherapy. Taiwan J
Obstet Gynecol 2004;43:20–4.
7. Tambaro R, Scambia G, Di Maio M, Pisano C, Barletta E,
Iaffaioli VR, Pignata S. The role of chemotherapy in locally
advanced, metastatic and recurrent cervical cancer. Crit Rev
Oncol Hematol 2004;52:33–44.
8. Lasic DD. Doxorubicin in sterically stabilized liposomes.
Nature 1996;380:561–2.
9. Verschraegen CF, Kavanagh JJ, Loyer E, et al; Community
Clinical Oncology Program. Phase II study of carboplatin
and liposomal doxorubicin in patients with recurrent squa-
mous cell carcinoma of the cervix. Cancer 2001;92:2327–33.
10. O’Byrne KJ, Bliss P, Graham JD, et al. A phase III study of
Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-
naive relapsed ovarian cancer. Proc Am Soc Clin Oncol 2002;
21:203a. [Abstract 808]
11. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME,
Lacave AJ. Recurrent epithelial ovarian carcinoma: a random-
ized phase III study of pegylated liposomal doxorubicin 
versus topotecan. J Clin Oncol 2001;19:3312–22.
12. Gordon AN, Tonda M, Sun S, Rackoff W; Doxil Study
30–49 Investigators. Long-term survival advantage for women
treated with pegylated liposomal doxorubicin compared
with topotecan in a phase 3 randomized study of recurrent
and refractory epithelial ovarian cancer. Gynecol Oncol
2004;95:1–8.
13. Woll PJ, Carmichael J, Chan S, Howell A, Ranson M, Miles D,
Welbank H. Phase II study results on safety and tolerability
of Caelyx® (Doxil®) in combination with paclitaxel in the
treatment of metastatic breast cancer. Proc Am Soc Clin
Oncol 1999:18:117a. [Abstract 442]
14. Harrison M, Tomlinson D, Stewart S. Liposomal-entrapped
doxorubicin: an active agent in AIDS-related Kaposi’s 
sarcoma. J Clin Oncol 1995;13:914–20.
15. Chou HH, Wang KL, Chen CA, et al; Taiwanese
Gynecologic Oncology Group. Pegylated liposomal doxoru-
bicin (Lipo-Dox) for platinum-resistant or refractory epithe-
lial ovarian carcinoma: a Taiwanese gynecologic oncology
group study with long-term follow-up. Gynecol Oncol 2006;
101:423–8.
16. Lorusso D, Naldini A, Testa A, D’Agostino G, Scambia G,
Ferrandina G. Phase II study of pegylated liposomal dox-
orubicin in heavily pretreated epithelial ovarian cancer
patients. Oncology 2004;67:243–9.
17. Martin FJ, Gabizon A, et al. Human pharmacokinetics of
stealth liposomes containing doxorubicin. J Cell Biochem
1992;50(Suppl 16E):98.
18. Gabizon A. Liposomal anthracyclines. Hematol Oncol Clin
North Am 1994;8:431–50.
19. Ferrandina G, Lorusso D, Longo R, Testa AC, Scambia G.
Pegylated liposomal doxorubicin in platinum-treated recur-
rent or metastatic cervical carcinoma. Gynecol Oncol 2005;
98:332–3.
20. Rose PG, Blessing JA, Lele S, Abulafia O. Evaluation of
pegylated liposomal doxorubicin (Doxil) as second-line
chemotherapy of squamous cell carcinoma of the cervix: a
phase II study of the Gynecologic Oncology Group. Gynecol
Oncol 2006;102:210–3.
